Italia markets closed

Sana Biotechnology, Inc. (SANA)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
7,51-0,22 (-2,91%)
In data: 01:00PM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente7,73
Aperto7,63
Denaro7,47 x 100
Lettera7,51 x 100
Min-Max giorno7,39 - 7,84
Intervallo di 52 settimane2,74 - 12,00
Volume987.288
Media Volume1.990.651
Capitalizzazione1,654B
Beta (5 anni mensile)1,61
Rapporto PE (ttm)N/D
EPS (ttm)-1,46
Prossima data utili06 mag 2024 - 10 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A11,17
  • GlobeNewswire

    Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M

    Increasing focus on ex vivo cell therapy platform based on extensive preclinical and early translational clinical data suggesting ability of hypoimmune (HIP)-modified cells to evade immune detection Human proof of concept data in multiple clinical settings – including oncology, autoimmune diseases, and type 1 diabetes – expected in 2023 and 2024 IND submitted to investigate SC291 in multiple B-cell-mediated autoimmune diseases with initial proof of concept data expected in 2024 Enrollment contin

  • GlobeNewswire

    Sana Biotechnology to Present at September 2023 Investor Conferences

    SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer, and Nate Hardy, Sana’s Chief Financial Officer. Steve Harr will present at Citi’s 18th Annual BioPharma Conferenc

  • GlobeNewswire

    Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates

    Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year Expect data later this year from investigator-sponsored trial with hypoimmune-modified primary human islet cells Goal to submit INDs this year for both SC262 and SG299 in hematologic cancers Hosted R&D Day, showcasing broad portfolio across platforms, programs, and diseases Announced plan to develop SC291 in autoimmune disorders Shared preclinical data that transplanted all